



DRY EYE SYNDROME: PATHOPHYSIOLOGY, DIAGNOSIS AND PREVENTIVE STRATEGIES

Hodiev Khushnudbek Ahmad ugli

Asia International University, Bukhara, Uzbekistan

Abstract. Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disorder of the tear film and ocular surface, characterized by tear film instability, hyperosmolarity, ocular discomfort, and visual disturbances. DES affects millions worldwide, significantly reducing quality of life and productivity. This review synthesizes current scientific understanding of DES pathophysiology, risk factors, diagnostic criteria, and evidence-based preventive strategies.

Keywords: Dry Eye Syndrome; Keratoconjunctivitis Sicca; Tear Film Instability; Tear Hyperosmolarity; Ocular Surface Inflammation; Meibomian Gland Dysfunction; Ocular Surface Disease; Lacrimal Gland Dysfunction; Tear Break-Up Time; Schirmer Test; Digital Eye Strain; Ocular Surface Homeostasis; Omega-3 Fatty Acids; Preventive Ophthalmology.

1. Introduction

Dry Eye Syndrome is a common ocular condition with increasing prevalence due to aging populations, environmental exposures, and widespread digital device use. The Tear Film & Ocular Surface Society's Dry Eye Workshop II (TFOS DEWS II) defines DES as a loss of homeostasis of the tear film accompanied by ocular symptoms, with tear film instability and hyperosmolarity, inflammation, and neurosensory abnormalities playing etiological roles.

Prevention and early intervention are critically important to reduce chronic morbidity, healthcare costs, and sequelae such as corneal epithelial damage and infectious keratitis.

2. Epidemiology

DES prevalence varies geographically but affects approximately 5–50% of adults, with higher rates in older individuals and females. Risk increases with age, systemic disease (e.g., autoimmune disorders), hormonal changes, and environmental exposures. The condition is frequently underdiagnosed due to symptom variability and patients' adaptation to discomfort.

3. Pathophysiology

3.1 Tear Film Composition and Function

The tear film comprises three layers:

- Lipid layer (outer) – produced by meibomian glands; reduces evaporation.
- Aqueous layer (middle) – secreted by lacrimal glands; provides hydration and nutrients.
- Mucin layer (inner) – secreted by goblet cells; ensures tear film adherence to the cornea.



DES develops from imbalance within one or more of these components.

3.2 Mechanisms of DES

3.2.1 Tear Hyperosmolarity

Elevated osmolarity damages epithelial cells and triggers inflammation.

3.2.2 Inflammation

Chronic inflammation mediated by cytokines (e.g., IL-1 β , TNF- α) disrupts tear production and ocular surface integrity.

3.2.3 Meibomian Gland Dysfunction (MGD)

MGD leads to deficient lipid secretion, increased evaporation, and tear instability.

3.2.4 Neurosensory Abnormalities

Impaired corneal nerve function alters reflex tear secretion and pain perception.

4. Clinical Manifestations

Typical symptoms include:

- Dryness, grittiness, burning
- Redness and irritation
- Blurred vision
- Eye fatigue, especially with screen use
- Excess tearing as reflex response

Symptoms may fluctuate with environmental conditions (wind, dry air) or prolonged visual tasks.

5. Diagnosis

A comprehensive evaluation includes:

5.1 Symptom Questionnaires

- Ocular Surface Disease Index (OSDI)
- Standard Patient Evaluation of Eye Dryness (SPEED)

5.2 Clinical Tests

- Tear Break-Up Time (TBUT) – assesses tear film stability.
- Schirmer's Test – measures tear quantity.
- Osmolarity Testing – quantifies tear hyperosmolarity.
- Ocular Surface Staining – evaluates epithelial damage using fluorescein or lissamine green.

5.3 Meibomian Gland Assessment

Meibography and expressibility scoring identify MGD contribution.



6. Risk Factors

6.1 Intrinsic Factors

- Age (higher in elderly)
- Female sex and hormonal changes (e.g., menopause)
- Autoimmune disorders (e.g., Sjögren syndrome, rheumatoid arthritis)
- Diabetes mellitus
- Contact lens wear

6.2 Extrinsic Factors

- Prolonged digital device use
- Low humidity or air pollutants
- Smoking
- Certain medications (antihistamines, antidepressants, isotretinoin)

7. Preventive Strategies

Prevention aims at improving tear film homeostasis, minimizing risk exposures, and addressing modifiable lifestyle factors.

7.1 Environmental and Occupational Modifications

- Avoid direct airflow from fans, air conditioners.
- Take regular breaks during screen tasks (20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds).
- Optimize workplace ergonomics with proper eye level screens.

7.2 Behavioral Interventions

- Blink consciously during prolonged visual tasks; complete full blinks.
- Limit excessive digital device time.
- Wear wraparound protective eyewear outdoors to reduce wind/evaporation.

7.3 Nutritional and Systemic Measures

- Omega-3 fatty acids (fish oil) supplementation may improve tear quality and reduce inflammation.
- Adequate hydration ensures systemic and ocular surface moisture.
- Treat underlying systemic conditions (e.g., diabetes, autoimmune disorders).

7.4 Eyelid Hygiene and Meibomian Gland Care

For early MGD:

- Warm compresses (40–45°C) for 5–10 minutes daily.
- Lid massage to improve lipid secretion.
- Lid scrubs for blepharitis control.

7.5 Education and Regular Screening

- At-risk populations (elderly, contact lens users) should receive education on early DES signs.



- Routine eye examinations facilitate early detection and intervention.

8. Discussion

DES is a complex condition with significant morbidity, yet it remains underrecognized. Multifactorial etiology necessitates a multidisciplinary approach that integrates environmental control, behavioral modification, nutritional support, and targeted ocular therapies.

Although artificial tears and pharmacologic agents (e.g., cyclosporine, lifitegrast) play substantial roles in management, prevention remains essential to reducing disease progression and improving outcomes.

9. Conclusion

Dry Eye Syndrome is a prevalent, multifactorial ocular surface disease with significant impact on visual function and quality of life. Evidence-based preventive strategies including environmental adjustments, lifestyle changes, blink training, and early management of meibomian gland dysfunction are critical in mitigating disease onset and severity. Continued research into pathophysiological mechanisms will refine preventive and therapeutic approaches. Maintain ambient humidity (>40%) using humidifiers.

References.

1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. *Ocul Surf.* 2017;15(3):276–283.
2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. *Ocul Surf.* 2017;15(3):334–365.
3. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benitez-Del-Castillo J, et al. Revisiting the vicious circle of dry eye disease. *Br J Ophthalmol.* 2016;100(3):300–306.
4. Lemp MA, Bron AJ, Baudouin C, Benítez Del Castillo JM, Geffen D, Tauber J, et al. Tear osmolarity in the diagnosis and management of dry eye disease. *Am J Ophthalmol.* 2011;151(5):792–798.
5. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction. *Ocul Surf.* 2017;15(3):269–275.
6. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. *Invest Ophthalmol Vis Sci.* 2011;52(4):1922–1929.
7. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II Pathophysiology Report. *Ocul Surf.* 2017;15(3):438–510.



8. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. *Ocul Surf.* 2017;15(3):575–628.
9. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome. *Am J Clin Nutr.* 2005;82(4):887–893.
10. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. *Am J Ophthalmol.* 2003;136(2):318–326.
11. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. *Dtsch Arztebl Int.* 2015;112(5):71–82.
12. McMonnies CW. Inflammation and dry eye. *Clin Exp Optom.* 2017;100(5):500–511.